Equities
  • Price (MXN)6,122.75
  • Today's Change0.00 / 0.00%
  • Shares traded627.00
  • 1 Year change+15.30%
  • Beta0.6913
Data delayed at least 20 minutes, as of Dec 18 2025 11:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

  • Revenue in USD (TTM)325.78bn
  • Net income in USD1.63bn
  • Incorporated2001
  • Employees51.00k
  • Location
    Cencora Inc1 West First AvenueCONSHOHOCKEN 19428United StatesUSA
  • Phone+1 (302) 658-7581
  • Fax+1 (302) 655-5049
  • Websitehttps://www.cencora.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
COR:NYQ since
announced
Transaction
value
OneOncology LLCDeal completed15 Dec 202515 Dec 2025Deal completed3.83%4.90bn
Nextpharma Logistics GmbHAnnounced13 Oct 202513 Oct 2025Announced12.97%--
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.